Search results
Moderna Says FDA Delaying Decision on RSV Vaccine Approval
Bloomberg· 6 days agoHave a confidential tip for our reporters? US regulators’ decision on whether to approve Moderna...
FDA Delays Decision on Moderna RSV Shot by 3 Weeks
Barrons.com· 6 days agoThe agency was originally scheduled to announce its call on Sunday. The company said it hadn’t flagged any issues with the drug’s safety, efficacy, or...
Novavax, Nvidia, Sweetgreen rise premarket; Moderna, Yelp fall By Investing.com
Investing.com· 6 days agoNovavax, Nvidia, Sweetgreen rise premarket; Moderna, Yelp fall
Benjamin F. Edwards & Company Inc. Raises Holdings in Moderna, Inc. (NASDAQ:MRNA)
ETF DAILY NEWS· 5 days agoBenjamin F. Edwards & Company Inc. raised its stake in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 17.2% during the 4th quarter, according to its most recent filing ...
FDA delays decision date for Moderna's RSV vaccine - Boston Business Journal
The Business Journals· 6 days agoJust days before its deadline, the U.S. Food and Drug Administration says it's giving itself more...
FDA delays decision on Moderna's RSV shot until the end of May
FierceBiotech· 6 days agoModerna will have to consider that after receiving word that the FDA will not meet a May 12 decision...
Moderna shares target raised to $85 by Deutsche Bank By Investing.com
Investing.com· 7 days agoOn Thursday, Deutsche Bank (ETR:DBKGn) revised its price target for Moderna (NASDAQ:MRNA) shares,...
Is Moderna Inc (MRNA) Set to Underperform? Analyzing the Factors
Guru Focus· 2 days agoLong-established in the Biotechnology industry, Moderna Inc (MRNA, Financial) has enjoyed a stellar reputation. Notably, its diminished rankings in financial strength, growth ...
Bull Market and Beyond: 2 Stocks Just Waiting to Soar
Motley Fool via Yahoo Finance· 3 days agoThough it might be tempting to invest in stocks that have largely been in tandem with the broader...
Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine
Zacks· 3 days agoFree Report) were down 4.4% on May 10 after the company announced that the FDA has delayed the review timeline for its mRNA-based, respiratory syncytial virus (RSV) vaccine, mRNA-1345.